U.S. Markets open in 2 mins.

Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
133.85-0.46 (-0.34%)
At close: 4:00PM EDT

133.25 -0.60 (-0.45%)
Pre-Market: 8:50AM EDT

People also watch
GILDBIIBREGNAMGNALXN
Full screen
Previous Close134.31
Open134.23
Bid133.25 x 900
Ask135.00 x 100
Day's Range132.56 - 134.44
52 Week Range96.06 - 135.18
Volume3,883,232
Avg. Volume3,819,760
Market Cap104.51B
Beta1.51
PE Ratio (TTM)50.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 24/7 Wall St.39 minutes ago

    Major Biotech Short Interest Surges

    The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.

  • Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone
    Investor's Business Daily17 hours ago

    Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone

    With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.

  • Barrons.com19 hours ago

    Seattle Genetics: A Disappointing Study…Or Was It?

    Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.